Precigen, Inc.
PGENNASDAQHealthcare● Active
$3.53
$-0.05(-1.40%)
Market Cap$1.1B
P/E Ratio—
52W High$5.47
52W Low$1.3
Precigen, Inc. (PGEN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PGEN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.02
Est. -$0.03 · +33.3%
Revenue
$0.02B
Est. $0.02B · +11.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
PGEN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.40
Rev. $5.46B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.40
Rev. Est.$5.46B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.02 | — | — | — | $0.03B | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$0.03 | -$0.02 | +33.3% | $0.02B | $0.02B | +11.8% |
| ▲ Q1 FY2026 | Mar 25, 2026 | -$0.10 | -$0.01 | +90.0% | $0.00B | $0.01B | -45.6% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$0.08 | -$0.11 | -37.5% | $0.00B | $0.01B | -64.7% |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.14 | -$0.11 | +21.4% | $0.00B | $0.00B | -8.3% |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.08 | -$0.07 | +12.5% | $0.00B | $0.00B | +168.2% |
| ▲ Q1 FY2025 | Mar 19, 2025 | -$0.06 | -$0.04 | +33.3% | $0.00B | $0.00B | +62.3% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.08 | -$0.09 | -12.5% | $0.00B | $0.00B | -26.7% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.02
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
-$0.02
EPS Est.
-$0.03
EPS Surpr.
+33.3%
Revenue
$0.02B
Q1 FY2026
Mar 25, 2026Beat
EPS Actual
-$0.01
EPS Est.
-$0.10
EPS Surpr.
+90.0%
Revenue
$0.00B
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$0.11
EPS Est.
-$0.08
EPS Surpr.
-37.5%
Revenue
$0.00B
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.11
EPS Est.
-$0.14
EPS Surpr.
+21.4%
Revenue
$0.00B
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.07
EPS Est.
-$0.08
EPS Surpr.
+12.5%
Revenue
$0.00B
Q1 FY2025
Mar 19, 2025Beat
EPS Actual
-$0.04
EPS Est.
-$0.06
EPS Surpr.
+33.3%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.09
EPS Est.
-$0.08
EPS Surpr.
-12.5%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.11 | $0.12 | $0.13 | 1 |
| Q3 FY2027 | $0.09 | $0.10 | $0.10 | 1 |
| Q2 FY2027 | $0.07 | $0.07 | $0.07 | 1 |
| Q1 FY2027 | $0.05 | $0.05 | $0.06 | 1 |
| Q4 FY2026 | $0.01 | $0.01 | $0.01 | 1 |
| Q3 FY2026 | $-0.01 | $-0.00 | $0.01 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +33.3% | $4.08 | $4.15 | +1.72% |
| ▲ Q1 FY2026 | Mar 25, 2026 | +90.0% | $3.13 | $3.10 | -0.96% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -37.5% | $4.02 | $3.86 | -3.98% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +21.4% | $1.74 | $1.80 | +3.45% |
| ▲ Q2 FY2025 | May 14, 2025 | +12.5% | $1.35 | $1.28 | -5.19% |
| ▲ Q1 FY2025 | Mar 19, 2025 | +33.3% | $1.67 | $1.79 | +7.19% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -12.5% | $0.92 | $0.88 | -3.58% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -11.1% | $1.09 | $1.12 | +2.75% |
Q2 FY2026+1.72%
Report Date
May 13, 2026
EPS Beat/Miss
+33.3%
Price Before
$4.08
Price After
$4.15
Q1 FY2026-0.96%
Report Date
Mar 25, 2026
EPS Beat/Miss
+90.0%
Price Before
$3.13
Price After
$3.10
Q4 FY2025-3.98%
Report Date
Nov 13, 2025
EPS Beat/Miss
-37.5%
Price Before
$4.02
Price After
$3.86
Q3 FY2025+3.45%
Report Date
Aug 12, 2025
EPS Beat/Miss
+21.4%
Price Before
$1.74
Price After
$1.80
Q2 FY2025-5.19%
Report Date
May 14, 2025
EPS Beat/Miss
+12.5%
Price Before
$1.35
Price After
$1.28
Q1 FY2025+7.19%
Report Date
Mar 19, 2025
EPS Beat/Miss
+33.3%
Price Before
$1.67
Price After
$1.79
Q4 FY2024-3.58%
Report Date
Nov 14, 2024
EPS Beat/Miss
-12.5%
Price Before
$0.92
Price After
$0.88
Q3 FY2024+2.75%
Report Date
Aug 14, 2024
EPS Beat/Miss
-11.1%
Price Before
$1.09
Price After
$1.12
Avg Beat Reaction+1.24%
Avg Miss Reaction-1.60%
Beat Rate5 / 8 quarters
Largest Move+7.19% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PGEN ends December
Precigen, Inc. (PGEN) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.02 — beating the analyst consensus of $-0.03 by +33.3%. PGEN has beaten EPS estimates for 2 consecutive quarters. The next PGEN earnings date is expected around September 1, 2026.
Each quarter, investors track PGEN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PGEN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PGEN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PGEN earnings · 5 questionsPrecigen, Inc.'s next earnings report is expected around September 1, 2026. PGEN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PGEN historically reports after market close (AMC).
PGEN earnings datewhen is PGEN earningsPGEN next earnings datewhen does PGEN report earningsPGEN earnings calendar
▸ Source: FMP · Precigen, Inc. SEC filings · US GAAP · Precigen, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026